噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢阻肺重叠综合征的临床效果分析

Clinical effect analysis of tiotropium bromide combined with salmeterol/fluticasone in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome

目的探究噻托溴铵联合沙美特罗/氟替卡松治疗哮喘-慢性阻塞性肺疾病(慢阻肺)重叠综合征的临床效果。方法 192例哮喘-慢阻肺重叠综合征患者,采用信封随机分组模式分为常规组和实验组,每组96例。常规组患者采用沙美特罗/氟替卡松治疗,实验组在常规组基础上联合噻托溴铵治疗。比较两组患者治疗前后生活质量评分、疾病发作情况。结果治疗前,两组患者生活质量评分比较差异无统计学意义(P>0.05);治疗后,实验组患者生活质量评分为(93.22±5.30)分,高于常规组的(75.23±5.36)分,差异具有统计学意义(P<0.05)。治疗前,两组患者急性发作次数、发作间隔时间比较差异无统计学意义(P>0.05);治疗后,实验组患者急性发作次数(3.35±1.22)次/年,明显低于常规组的(11.23±3.21)次/年,发作间隔时间(78.52±8.63)d长于常规组的(35.46±8.69)d,差异具有统计学意义(P<0.05)。结论对哮喘-慢阻肺重叠综合征患者给予噻托溴铵联合沙美特罗/氟替卡松进行治疗,能够改善患者的临床症状,提高生活质量。

Objective To investigate the clinical effect of tiotropium bromide combined with salmeterol/fluticasone in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome. Methods A total of 192 patients with asthma-chronic obstructive pulmonary disease overlap syndrome were divided by envelope random grouping mode into conventional group and experimental group, with 96 cases in each group. The conventional group was treated with salmeterol/fluticasone, and the experimental group was treated with tiotropium bromide on the basis of the conventional group. The quality of life scores and disease episodes before and after treatment in the two groups were compared. Results Before treatment, there was no statistically significant difference in quality of life score（P〈0.05）. After treatment, the experimental group had higher quality of life score as（93.22±5.30） points than（75.23±5.36） points in the conventional group, and the difference was statistically significant（P〈0.05）. Before treatment, there was no statistically significant difference in frequency of acute attacks, interval between attacks（P〈0.05）. After treatment, the experimental group had obviously less frequency of acute attacks as（3.35±1.22） times/year than（11.23±3.21） times/year in the conventional group, and longer interval between attacks as（78.52±8.63） d than（35.46±8.69） d in conventional group. Their difference was statistically significant（P〈0.05）. Conclusion Combination of tiotropium bromide and salmeterol/fluticasone can significantly improve the clinical symptom of patients with asthma-chronic obstructive pulmonary disease overlap syndrome, and improve their quality of life.